Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Kandzari, MD
Piedmont Heart Institute
Principal Investigator - Jacques Koolen, MD
Catharina Ziekenhuis
Principal Investigator - Ron Waksman, MD
Medstar Health Research Institute
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
92 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Adelaide, Australia
- Facility name not stated
Genk, Belgium
- Facility name not stated
Leuven, Belgium
- Facility name not stated
Roeselare, Belgium
- Facility name not stated
Calgary, Alberta, Canada
- Facility name not stated
Aarhus, Denmark
- Facility name not stated
Bad Segeberg, Germany
- Facility name not stated
Berlin, Germany
- Facility name not stated
Berlin, Germany
- Facility name not stated
Hamburg, Germany
- Facility name not stated
Minden, Germany
- Facility name not stated
Neuss, Germany
- Facility name not stated
Budapest, Hungary
- Facility name not stated
Pécs, Hungary
- Facility name not stated
Szeged, Hungary
- Facility name not stated
Haifa, Israel
- Facility name not stated
Jerusalem, Israel
- Facility name not stated
Petah Tikva, Israel
- Facility name not stated
Rehovot, Israel
- Facility name not stated
Tel Aviv, Israel
- Facility name not stated
Breda, Netherlands
- Facility name not stated
Eindhoven, Netherlands
- Facility name not stated
Nieuwegein, Netherlands
- Facility name not stated
Auckland, New Zealand
- Facility name not stated
Daegu, South Korea
- Facility name not stated
Gwangju, South Korea
- Facility name not stated
Seoul, South Korea
- Facility name not stated
Seoul, South Korea
- Facility name not stated
Seoul, South Korea
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Málaga, Spain
- Facility name not stated
Seville, Spain
- Facility name not stated
Lausanne, Switzerland
- Facility name not stated
Zurich, Switzerland
- Facility name not stated
Zurich, Switzerland
- Facility name not stated
Fairhope, Alabama, United States
- Facility name not stated
Concord, California, United States
- Facility name not stated
La Mesa, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2015
- Primary completion
- 30 Apr 2017
- Completion
- 31 Mar 2021
- Last update posted
- 3 Aug 2022
- Registered enrollment
- 1,334
- Registry id
- NCT02389946
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.